Baird Downgrades Ambrx Biopharma to Neutral, Announces $28 Price Target

Moomoo 24/7 ·  Jan 16 14:38

Baird analyst Joel Beatty downgrades Ambrx Biopharma (NASDAQ:AMAM) from Outperform to Neutral and announces $28 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment